Artelo Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Artelo Biosciences, Inc. carries a market capitalization of 13,069.00, placing it among publicly traded companies globally. Its enterprise value stands at -4.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13,069.00 |
| Enterprise Value | -4.15M |
Share Statistics
Artelo Biosciences, Inc. currently has 3.49M shares outstanding.
| Shares Outstanding | 3.49M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Artelo Biosciences, Inc. maintains a current ratio of 3.00, meaning it holds 3.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.98, indicating moderate leverage, while an interest coverage ratio of -33.04 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.00 |
| Quick Ratio | 2.89 |
| Debt / Equity | 0.98 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | -33.04 |
Financial Efficiency
| Return on Equity (ROE) | -367.70 |
| Return on Assets (ROA) | -234.30 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Artelo Biosciences, Inc.'s stock has declined approximately -88.8% over the past 52 weeks. The 50-day moving average sits at - -, while the 200-day moving average is - -.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.8% |
| 50-Day Moving Average | - - |
| 200-Day Moving Average | - - |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.07M, while operating income came in at -11.07M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.07M |
| Pretax Income | -12.67M |
| Net Income | -12.67M |
| EBITDA | -11.07M |
| EBIT | -11.07M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Artelo Biosciences, Inc. holds 4.20M in cash and equivalents against 49,000.00 in total debt, resulting in a net debt position of -4.20M. Total book value stands at 5.00M, with working capital of 2.92M providing operational flexibility.
| Cash & Cash Equivalents | 4.20M |
| Total Debt | 49,000.00 |
| Net Debt | -4.20M |
| Equity (Book Value) | 5.00M |
| Book Value Per Share | 1.43 |
| Working Capital | 2.92M |
Cash Flow
Artelo Biosciences, Inc. produced -12.63M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.63M |
| Capital Expenditures | N/A |
| Free Cash Flow | -12.63M |
| FCF Per Share | N/A |
Scores
Artelo Biosciences, Inc. posts an Altman Z-Score of -29.14, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.14 |